MTOR and breast cancer: In MMTV-erbB-2 transgenic mice which can be induced to develop breast cancer, treatment with buformin deactivated many signaling pathways including mTOR, ER, and β-catenin and eventually significantly impaired the stemness of breast cancer cells [19].